VSA-2(VSA-2) - 在研适应症：自身免疫性疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点-

作用机制

免疫刺激剂

治疗领域

免疫系统疾病

在研适应症

自身免疫性疾病

非在研适应症-

原研机构

The University of Alabama

在研机构

The University of Alabama

非在研机构-

最高研发阶段药物发现

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 VSA-2 相关的临床结果

登录后查看更多信息

100 项与 VSA-2 相关的转化医学

登录后查看更多信息

100 项与 VSA-2 相关的专利（医药）

登录后查看更多信息

1

项与 VSA-2 相关的文献（医药）

2022-11-10·Journal of Medicinal Chemistry1区 · 医学

Structure–Activity Relationship Study of Momordica Saponin II Derivatives as Vaccine Adjuvants

1区 · 医学

Article

作者: Ghosh, Sadashib ; Wang, Pengfei ; Michalek, Suzanne M. ; Leavenworth, Jianmei W. ; Bai, Di ; Liu, Zheng ; Kim, Hyunjung ; Zhang, Ping ; Wang, Xifeng ; Yan, Cheng ; Franks, Michael L.

VSA-2 is a recently developed semisynthetic saponin immunostimulant. It is prepared by incorporating a terminal-functionalized side chain to the branched trisaccharide domain at the C3 position of Momordica saponin II (MS II) isolated from the seeds of perennial Momordica cochinchinensis Spreng. Direct comparison of VSA-2 and the clinically proven saponin adjuvant QS-21 shows that VSA-2 is comparable to QS-21 in enhancing humoral and cellular immune responses. Structure-activity relationship studies show that structural changes in the side chain have a significant impact on saponins' adjuvant activity. However, with the VSA-2 molecular framework intact, the new VSA-2 analogues with various substitution(s) at the terminal benzyl group of the side chain retain the ability of potentiating antigen-specific humoral and cellular responses.

100 项与 VSA-2 相关的药物交易

登录后查看更多信息